Marshall Financial Group LLC Buys New Holdings in Abbott Laboratories $ABT

Key Points

• Marshall Financial Group LLC has acquired a new stake in Abbott Laboratories, purchasing 14,464 shares valued at approximately $1.93 million during the 2nd quarter.
• Abbott Laboratories reported revenue of $11.14 billion for the latest quarter, exceeding estimates, and maintained earnings guidance of $5.100-5.200 EPS for FY 2025.
• Analysts show a *consensus rating of "Moderate Buy"* for Abbott Laboratories, with target prices varying from $140 to $147 following recent broker upgrades and downgrades.

Marshall Financial Group LLC bought a new position in shares of Abbott Laboratories (NYSE:ABT - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 14,464 shares of the healthcare product maker's stock, valued at approximately $1,934,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Brighton Jones LLC raised its holdings in shares of Abbott Laboratories by 10.1% during the 4th quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker's stock worth $5,850,000 after acquiring an additional 4,755 shares during the period. Bank Pictet & Cie Europe AG raised its holdings in shares of Abbott Laboratories by 1.9% during the 4th quarter. Bank Pictet & Cie Europe AG now owns 152,719 shares of the healthcare product maker's stock worth $17,274,000 after acquiring an additional 2,774 shares during the period. Vident Advisory LLC raised its holdings in shares of Abbott Laboratories by 30.2% during the 4th quarter. Vident Advisory LLC now owns 34,899 shares of the healthcare product maker's stock worth $3,948,000 after acquiring an additional 8,098 shares during the period. Woodline Partners LP purchased a new position in shares of Abbott Laboratories during the 4th quarter worth $5,997,000. Finally, Waverly Advisors LLC raised its holdings in shares of Abbott Laboratories by 19.1% during the 4th quarter. Waverly Advisors LLC now owns 87,165 shares of the healthcare product maker's stock worth $9,859,000 after acquiring an additional 13,952 shares during the period. Institutional investors and hedge funds own 75.18% of the company's stock.

Insider Transactions at Abbott Laboratories

In other Abbott Laboratories news, CFO Philip P. Boudreau sold 5,550 shares of the business's stock in a transaction dated Friday, August 8th. The shares were sold at an average price of $134.55, for a total transaction of $746,752.50. Following the sale, the chief financial officer directly owned 51,003 shares in the company, valued at $6,862,453.65. This represents a 9.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.46% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on ABT shares. Leerink Partnrs upgraded Abbott Laboratories to a "hold" rating in a report on Monday, June 16th. Raymond James Financial reduced their price target on Abbott Laboratories from $142.00 to $141.00 and set an "outperform" rating on the stock in a report on Friday, July 18th. Morgan Stanley boosted their price objective on shares of Abbott Laboratories from $127.00 to $137.00 and gave the company an "equal weight" rating in a report on Tuesday, July 15th. Mizuho boosted their price objective on shares of Abbott Laboratories from $130.00 to $140.00 and gave the company a "neutral" rating in a report on Wednesday, July 16th. Finally, Leerink Partners assumed coverage on shares of Abbott Laboratories in a report on Monday, June 16th. They issued a "market perform" rating and a $143.00 price objective on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Abbott Laboratories presently has a consensus rating of "Moderate Buy" and a consensus target price of $145.22.

Abbott Laboratories Trading Up 1.2%

NYSE:ABT traded up $1.65 on Friday, reaching $136.22. 11,531,874 shares of the company's stock were exchanged, compared to its average volume of 4,828,819. The company has a quick ratio of 1.30, a current ratio of 1.82 and a debt-to-equity ratio of 0.25. The firm has a market capitalization of $237.09 billion, a price-to-earnings ratio of 17.07, a price-to-earnings-growth ratio of 2.55 and a beta of 0.69. The business has a fifty day moving average of $130.47 and a 200-day moving average of $131.19. Abbott Laboratories has a 52-week low of $110.86 and a 52-week high of $141.23.

Abbott Laboratories (NYSE:ABT - Get Free Report) last issued its quarterly earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $1.26. The company had revenue of $11.14 billion for the quarter, compared to analyst estimates of $11.01 billion. Abbott Laboratories had a net margin of 32.43% and a return on equity of 18.32%. The business's revenue for the quarter was up 7.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.14 earnings per share. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. As a group, analysts expect that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, November 17th. Shareholders of record on Wednesday, October 15th will be paid a dividend of $0.59 per share. The ex-dividend date is Wednesday, October 15th. This represents a $2.36 dividend on an annualized basis and a yield of 1.7%. Abbott Laboratories's dividend payout ratio is 29.57%.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.